165 related articles for article (PubMed ID: 15370223)
1. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
Chanan-Khan A; Islam T; Alam A; Miller KC; Gibbs J; Barcos M; Czuczman MS; Paplham P; Hahn T; McCarthy P
Leuk Lymphoma; 2004 Aug; 45(8):1673-5. PubMed ID: 15370223
[TBL] [Abstract][Full Text] [Related]
2. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma.
Wulf GG; Hasenkamp J; Jung W; Chapuy B; Truemper L; Glass B
Bone Marrow Transplant; 2005 Aug; 36(3):271-3. PubMed ID: 15937499
[No Abstract] [Full Text] [Related]
3. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
[TBL] [Abstract][Full Text] [Related]
6. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
[TBL] [Abstract][Full Text] [Related]
7. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
[TBL] [Abstract][Full Text] [Related]
8. Hepatosplenic gamma-delta T-cell lymphoma.
Ferreri AJ; Govi S; Pileri SA
Crit Rev Oncol Hematol; 2012 Aug; 83(2):283-92. PubMed ID: 22047938
[TBL] [Abstract][Full Text] [Related]
9. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
10. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
11. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
[TBL] [Abstract][Full Text] [Related]
12. Hepatosplenic T-cell lymphoma and TNF-α inhibitors.
Pozadzides JV; Pro B
Expert Rev Hematol; 2009 Dec; 2(6):611-4. PubMed ID: 21082951
[No Abstract] [Full Text] [Related]
13. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
15. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Peggs KS; Sureda A; Qian W; Caballero D; Hunter A; Urbano-Ispizua A; Cavet J; Ribera JM; Parker A; Canales M; Mahendra P; Garcia-Conde J; Milligan D; Sanz G; Thomson K; Arranz R; Goldstone AH; Alvarez I; Linch DC; Sierra J; Mackinnon S;
Br J Haematol; 2007 Oct; 139(1):70-80. PubMed ID: 17854309
[TBL] [Abstract][Full Text] [Related]
16. Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation.
Piccaluga PP; Martinelli G; Malagola M; Rondoni M; Bianchini M; Vigna E; Bosi C; Gaitani S; Visani G; Baccarani M
Leuk Lymphoma; 2004 Apr; 45(4):731-3. PubMed ID: 15160947
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
[TBL] [Abstract][Full Text] [Related]
18. Hepatosplenic γδ T-cell lymphoma of two adolescents: Case report and retrospective literature review in children, adolescents, and young adults.
McThenia SS; Rawwas J; Oliveira JL; Khan SP; Rodriguez V
Pediatr Transplant; 2018 Aug; 22(5):e13213. PubMed ID: 29921021
[TBL] [Abstract][Full Text] [Related]
19. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
[TBL] [Abstract][Full Text] [Related]
20. New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.
Schriever F; Huhn D
Drugs; 2003; 63(10):953-69. PubMed ID: 12699399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
